These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 1577391)

  • 61. A double-blind, controlled study comparing lafutidine with placebo and famotidine in Japanese patients with mild reflux esophagitis.
    Ohara S; Haruma K; Kinoshita Y; Kusano M
    J Gastroenterol; 2010 Dec; 45(12):1219-27. PubMed ID: 20632193
    [TBL] [Abstract][Full Text] [Related]  

  • 62. In vitro effects of famotidine and ranitidine on lower esophageal sphincter tone in rats.
    Özer M; Duman M; Taş Ş; Demırcı Y; Aydin MF; Reyhan E; Atici AE; Bostanci EB; Akoğlu M; Genç E
    Turk J Gastroenterol; 2012; 23(5):438-43. PubMed ID: 23161288
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Comparison of the effects between standard doses of H2-blocker (famotidine 20mg b.d.) and proton pump inhibitor (omeprazole 20mg o.d.) in the treatment of refractory reflux esophagitis by ambulatory 24-hr intra-gastroesophageal pH monitoring].
    Yamashita Y; Kinoshita Y; Chihara K; Chiba T
    Nihon Shokakibyo Gakkai Zasshi; 1994 Dec; 91(12):2166-73. PubMed ID: 7837683
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Ranitidine: a new H2-receptor antagonist.
    Zeldis JB; Friedman LS; Isselbacher KJ
    N Engl J Med; 1983 Dec; 309(22):1368-73. PubMed ID: 6314139
    [No Abstract]   [Full Text] [Related]  

  • 65. Cimetidine treatment of reflux esophagitis in children: an Italian multicentric study.
    Cucchiara S; Gobio-Casali L; Balli F; Magazzú G; Staiano A; Astolfi R; Amarri S; Conti-Nibali S; Guandalini S
    J Pediatr Gastroenterol Nutr; 1989 Feb; 8(2):150-6. PubMed ID: 2651632
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cimetidine 800 mg twice daily for healing erosions and ulcers in gastroesophageal reflux disease.
    Palmer RH; Frank WO; Rockhold FW; Wetherington JD; Young MD
    J Clin Gastroenterol; 1990; 12 Suppl 2():S29-34. PubMed ID: 2246493
    [TBL] [Abstract][Full Text] [Related]  

  • 67. 24-hour esophageal pH monitoring before and after medical therapy for reflux esophagitis.
    Lieberman DA
    Dig Dis Sci; 1988 Feb; 33(2):166-71. PubMed ID: 3338365
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Treatment of reflux oesophagitis with H2-receptor antagonists.
    Meuwissen SG; Klinkenberg-Knol EC
    Scand J Gastroenterol Suppl; 1988; 146():201-13. PubMed ID: 2906465
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Managing gastroesophageal reflux disease.
    Ray SW; Secrest J; Ch'ien AP; Corey RS
    Nurse Pract; 2002 May; 27(5):36-53; quiz 54-5. PubMed ID: 12037474
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pharmacokinetics and pharmacodynamics of famotidine in patients with reflux oesophagitis.
    Gladziwa U; Wagner S; Dakshinamurty KV; el Desoky E; Dreuw B; Klotz U
    Eur J Clin Pharmacol; 1993; 44(4):357-60. PubMed ID: 8513846
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Gastrin, gastric emptying, and gastroesophageal reflux after ranitidine.
    Sherbaniuk RW; Wensel R; Trautman A; Grace M; Lentle B; Walker K; Salkie M; Thomson AB
    J Clin Gastroenterol; 1983 Jun; 5(3):239-44. PubMed ID: 6306094
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparative efficacy of acid reflux inhibition by drug therapy in reflux esophagitis.
    Sekiguchi T; Nishioka T; Matsuzaki T; Sugiyama M; Kusano M; Horikoshi T; Toki M; Ohwada T; Kobayashi S
    Gastroenterol Jpn; 1991 Apr; 26(2):137-44. PubMed ID: 2040397
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Dose--response effect of famotidine on patterns of gastro-oesophageal reflux.
    Orr WC; Robinson MG; Humphries TJ; Antonello J; Cagliola A
    Aliment Pharmacol Ther; 1988 Jun; 2(3):229-35. PubMed ID: 2979247
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis.
    Wesdorp IC; Dekker W; Festen HP
    Dig Dis Sci; 1993 Dec; 38(12):2287-93. PubMed ID: 8261835
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A randomized, double-blind, placebo-controlled clinical study of the histamine H2-receptor antagonist famotidine in Japanese patients with nonerosive reflux disease.
    Hongo M; Kinoshita Y; Haruma K
    J Gastroenterol; 2008; 43(6):448-56. PubMed ID: 18600389
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Failure of sucralfate in the treatment of refractory esophagitis versus high-dose famotidine. An endoscopic study.
    Pace F; Lazzaroni M; Bianchi Porro G
    Scand J Gastroenterol; 1991 May; 26(5):491-4. PubMed ID: 1871541
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Treatment of reflux oesophagitis.
    de Carle D
    Med J Aust; 1983 Nov; 2(11):531-2. PubMed ID: 6314106
    [No Abstract]   [Full Text] [Related]  

  • 78. Drug usage evaluation: H2-receptor antagonist use in 30 hospitals.
    Kowalsky SF; Hamilton RA; Figge HL
    Hosp Formul; 1991 Sep; 26(9):725-6, 732, 734-6 passim. PubMed ID: 10114004
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Therapeutic principles in gastroesophageal reflux].
    Chassany O; Elkharrat D; Bergmann JF; Segrestaa JM
    Rev Med Interne; 1995; 16(12):960-70. PubMed ID: 8570962
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy of sucralfate in refractory reflux esophagitis. Results of a pilot study.
    Ros E; Pujol A; Bordas JM; Grande L
    Scand J Gastroenterol Suppl; 1989; 156():49-55. PubMed ID: 2740842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.